Latest publications

Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients-A BioCAPTURE Registry Study. Ter Haar ELM, Thomas SE, Van den Reek JMPA, Otero ME, Njoo MD, Ossenkoppele PM et al. Drugs Aging 2022 Jul 21

Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. Spekhorst LS, Bakker D, Drylewicz J, Rispens T, Loeff F, Boesjes CM et al. Allergy 2022 Jul 15

Recombinant human C1 esterase inhibitor as prophylactic treatment in idiopathic non-histaminergic angioedema. Alizadeh Aghdam M, Hofman ZLM, Meertens M, Lebens A, Hack CE, Knulst AC et al. Allergy 2022 Jul 15

Systemic treatment of children and adolescents with atopic dermatitis aged ≥2 years: a Delphi consensus project mapping expert opinion in Northern Europe. De Graaf M, Janmohamed SR, Schuttelaar MLA, Agner T, Alfonso JH, De Schepper S et al. J Eur Acad Dermatol Venereol 2022 Jul 06

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. De Bruin-Weller MS, Serra-Baldrich E, Barbarot S, Grond S, Schuster C, Petto H et al. Dermatol Ther (Heidelb) 2022 Jun; 12(6):1481-1491

Aesthetic Outcome of Propranolol vs Atenolol Treatment of Children with Infantile Haemangioma. Hermans MM, Breugem CC, Schappin R, Jonge Poerink E, Mendels EJ, Ragamin A et al. Acta Derm Venereol 2022 May 04

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Beck LA, Deleuran M, Bissonnette R, De Bruin-Weller M, Galus R, Nakahara T et al. Am J Clin Dermatol 2022 May; 23(3):393-408

Estimating the Risk of Severe Peanut Allergy Using Clinical Background and IgE Sensitization Profiles. Datema MR, Lyons SA, Fernández-Rivas M, Ballmer-Weber B, Knulst AC, Asero R et al. Front Allergy 2021; 2:670789

Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort. Van Muijen ME, Thomas SE, Groenewoud HMM, Otero ME, Ossenkoppele PM, Njoo MD et al. Acta Derm Venereol 2022 May 16; 102:adv00712

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study. Alexis A, De Bruin-Weller M, Weidinger S, Soong W, Barbarot S, Ionita I et al. Dermatol Ther (Heidelb) 2022 Mar; 12(3):771-785

Ocular surface disease is common in moderate-to-severe atopic dermatitis patients. Achten RE, Bakker DS, Van Luijk CM, Van der Wal M, De Graaf M, Van Wijk F et al. Clin Exp Allergy 2022 06; 52(6):801-805

Systemic glucocorticoid use and the occurrence of flares in psoriatic arthritis and psoriasis: a systematic review. Vincken NLA, Balak DMW, Knulst AC, Welsing PMJ, Van Laar JM et al. Rheumatology (Oxford) 2022 Mar 14

The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry. Voorberg AN, Romeijn GLE, De Bruin-Weller MS, Schuttelaar MLA et al. Contact Dermatitis 2022 Aug; 87(2):185-191

Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes. El Sharouni MA, Scolyer RA, Van Gils CH, Ch'ng S, Nieweg OE, Pennington TE et al. Eur J Cancer 2022 05; 167:123-132

Use of systemic therapies in adults with atopic dermatitis: 12-month results from the European prospective observational study in patients eligible for systemic therapy for atopic dermatitis (EUROSTAD). De Bruin-Weller M, Pink AE, Ferrucci SM, Patrizi A, Svensson A, Schuttelaar MLA et al. J Dermatolog Treat 2022 Mar 08:1-6